Synonyms:
Status: Phase 3
Entry Type: Antibody
Molecule Category: UNKNOWN
UNII: S3GQZ2K36V

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Programmed cell death protein 1 antagonist

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Small Cell Lung Carcinoma 3 D055752 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Stomach Neoplasms 3 D013274 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Carcinoma, Hepatocellular 3 D006528 ClinicalTrials
Uterine Cervical Neoplasms 3 D002583 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Stomach Neoplasms 3 D013274 ClinicalTrials
Esophageal Neoplasms 3 D004938 ClinicalTrials
Neoplasms 3 D009369 ClinicalTrials
Ascites 2 D001201 ClinicalTrials
Adenocarcinoma of Lung 2 D000077192 ClinicalTrials
Carcinoma, Renal Cell 2 D002292 ClinicalTrials
Nasopharyngeal Neoplasms 2 D009303 ClinicalTrials
Adenocarcinoma 2 D000230 ClinicalTrials
Colonic Neoplasms 2 D003110 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Colorectal Neoplasms 2 D015179 ClinicalTrials
Carcinoma, Neuroendocrine 1 D018278 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL4594550
FDA SRS S3GQZ2K36V